Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bristol-Myers, Novartis Cancer Drugs Are Under U.K. Cost Review

Don't Miss Out —
Follow us on:

May 6 (Bloomberg) -- Bristol-Myers Squibb Co.’s Sprycel and Novartis AG’s Tasigna are under review by the U.K. health-cost regulator for the treatment of a rare blood cancer because the benefits of the drugs may not justify their high prices.

The National Institute for Health and Clinical Excellence wasn’t able to recommend either medicine for patients whose chronic myeloid leukemia doesn’t respond to the standard dose of Novartis’s Glivec treatment, according to draft guidelines published today. A higher dose of Glivec also failed to win the agency’s backing for that group of patients.

The agency, known as NICE, advises the government-funded National Health Service on which treatments are the most cost-effective. Sprycel and Tasigna cost more than 30,000 pounds ($50,000) a year for each patient, NICE said in a statement. Novartis has raised the price of Glivec, also sold as Gleevec, to more than 40,000 pounds a year for the high dose, NICE said.

“When we recommend the use of a very expensive treatments, we need to be confident that they bring sufficient additional benefit to justify their cost,” NICE Chief Executive Officer Andrew Dillon said in the statement. Evidence supporting the use of Sprycel, Tasigna and high-dose Glivec in the hard-to-treat form of the disease “is very weak,” he said.

Chronic myeloid leukemia affects about 560 people in the U.K. each year, according to NICE. The illness requires treatment over a long period of time, making the cost to the health system even greater, NICE said.

The guidelines are open for public comments. Until final recommendations are issued, the National Health Service should make decisions on treatment locally, and people already receiving the drugs may continue with therapy, NICE said.

NICE is also reviewing the use of Sprycel and Tasigna by chronic myeloid leukemia patients who can’t take Glivec, and the use of Sprycel, Tasigna and the standard dose of Glivec as an initial treatment for those with the disease.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.